#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating pediatric drug-resistant epilepsy need to understand current NHS access barriers to medical cannabis, as evidence-based cannabinoid therapies have demonstrated efficacy in this population but remain unavailable through standard channels. This campaign highlights the gap between regulatory approval and clinical availability, directly affecting treatment options that clinicians can offer families of affected children. Awareness of these access limitations enables clinicians to better counsel patients on available alternatives and advocate for policy changes that could expand evidence-based treatment options.
This campaign addresses a significant access gap in UK medical cannabis practice, highlighting that children with drug-resistant epilepsy remain unable to obtain cannabis-based medicinal products through the NHS despite the 2018 legal change permitting specialist prescribing. The regulatory framework allows physician-led cannabis prescriptions for specific conditions including refractory epilepsy, yet NHS funding barriers and stringent access criteria have left eligible pediatric patients without realistic pathways to this evidence-supported treatment. The campaign advocates for government funding and streamlined NHS protocols to enable clinicians to prescribe cannabis medicines to children for whom conventional anticonvulsants have failed, a population with substantial unmet medical need and documented clinical benefit in some cases. For practitioners treating drug-resistant epilepsy in pediatric populations, this reflects the persistent gap between legal authorization and practical access, requiring awareness of private prescribing pathways and engagement with local NHS commissioning discussions. Clinicians should understand current NHS cannabis prescribing policies in their regions and discuss both available routes and ongoing advocacy efforts with families of affected children.
“We’ve known for over a decade that cannabidiol can be genuinely life-changing for children with severe, intractable seizure disorders, yet the gap between clinical evidence and actual patient access remains a profound failure of healthcare systems on both sides of the Atlantic. When families have to fight bureaucracies or leave their countries to access a medicine that could stop their child’s seizures, we’ve stopped practicing medicine and started practicing politics instead.”
🧠 While the UK’s 2018 decision to permit medical cannabis prescriptions for certain conditions including drug-resistant epilepsy represented important regulatory progress, implementation gaps have created a two-tiered access system where many eligible patients cannot obtain treatment through NHS channels. The clinical evidence base for cannabinoid efficacy in pediatric epilepsy, particularly for conditions like Dravet syndrome, is genuine but remains incomplete, with ongoing questions about optimal dosing, long-term safety profiles, and patient selection criteria that complicate straightforward clinical guidance. Clinicians face the difficult position of having patients who may benefit from cannabis-based medicines yet lack accessible pathways to prescribe them within standard care, while private options remain prohibitively expensive for most families. Advocacy efforts highlighting individual patient stories are understandable but should be accompanied by continued investment in rigorous clinical trials and transparent NHS commissioning frameworks that balance compassionate access with evidence standards. For practitioners managing children
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: